300 related articles for article (PubMed ID: 27288631)
1. Circulating lipocalin 2 is neither related to liver steatosis in patients with non-alcoholic fatty liver disease nor to residual liver function in cirrhosis.
Meier EM; Pohl R; Rein-Fischboeck L; Schacherer D; Eisinger K; Wiest R; Krautbauer S; Buechler C
Cytokine; 2016 Sep; 85():45-50. PubMed ID: 27288631
[TBL] [Abstract][Full Text] [Related]
2. Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt.
Trebicka J; Krag A; Gansweid S; Appenrodt B; Schiedermaier P; Sauerbruch T; Spengler U
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1218-25. PubMed ID: 21971377
[TBL] [Abstract][Full Text] [Related]
3. The relationship between Lipocalin-2 level and hepatic steatosis in obese patients with NAFLD after bariatric surgery.
Chen J; Lei S; Huang Y; Zha X; Gu L; Zhou D; Li J; Liu F; Li N; Du L; Huang X; Lin Z; Bu L; Qu S
Lipids Health Dis; 2022 Jan; 21(1):10. PubMed ID: 35034646
[TBL] [Abstract][Full Text] [Related]
4. Systemic saturated lysophosphatidylcholine is associated with hepatic function in patients with liver cirrhosis.
Krautbauer S; Eisinger K; Wiest R; Liebisch G; Buechler C
Prostaglandins Other Lipid Mediat; 2016 Jul; 124():27-33. PubMed ID: 27265202
[TBL] [Abstract][Full Text] [Related]
5. Liver lipocalin 2 expression in severely obese women with non alcoholic fatty liver disease.
Auguet T; Terra X; Quintero Y; Martínez S; Manresa N; Porras JA; Aguilar C; Orellana-Gavaldà JM; Hernández M; Sabench F; Lucas A; Pellitero S; Del Castillo D; Richart C
Exp Clin Endocrinol Diabetes; 2013 Feb; 121(2):119-24. PubMed ID: 23426707
[TBL] [Abstract][Full Text] [Related]
6. Reduced serum chemerin in patients with more severe liver cirrhosis.
Eisinger K; Krautbauer S; Wiest R; Weiss TS; Buechler C
Exp Mol Pathol; 2015 Apr; 98(2):208-13. PubMed ID: 25595667
[TBL] [Abstract][Full Text] [Related]
7. Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function.
Wanninger J; Weigert J; Wiest R; Bauer S; Karrasch T; Farkas S; Scherer MN; Walter R; Weiss TS; Hellerbrand C; Neumeier M; Schäffler A; Buechler C
Cytokine; 2011 Sep; 55(3):435-40. PubMed ID: 21715185
[TBL] [Abstract][Full Text] [Related]
8. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
[TBL] [Abstract][Full Text] [Related]
9. Connective tissue growth factor level is increased in patients with liver cirrhosis but is not associated with complications or extent of liver injury.
Bauer S; Eisinger K; Wiest R; Karrasch T; Scherer MN; Farkas S; Aslanidis C; Buechler C
Regul Pept; 2012 Nov; 179(1-3):10-4. PubMed ID: 22960408
[TBL] [Abstract][Full Text] [Related]
10. [Hepatic parenchimatous damage and perfusion disturbance in the progression of nonalcoholic fatty liver disease].
Dudanova OP; Belavina IA
Eksp Klin Gastroenterol; 2014; (8):41-5. PubMed ID: 25911911
[TBL] [Abstract][Full Text] [Related]
11. Steatosis and portal hypertension.
Puoti C; Bellis L
Eur Rev Med Pharmacol Sci; 2005; 9(5):285-90. PubMed ID: 16231591
[TBL] [Abstract][Full Text] [Related]
12. Lipocalin 2 drives neutrophilic inflammation in alcoholic liver disease.
Wieser V; Tymoszuk P; Adolph TE; Grander C; Grabherr F; Enrich B; Pfister A; Lichtmanegger L; Gerner R; Drach M; Moser P; Zoller H; Weiss G; Moschen AR; Theurl I; Tilg H
J Hepatol; 2016 Apr; 64(4):872-80. PubMed ID: 26682726
[TBL] [Abstract][Full Text] [Related]
13. Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients.
Feder S; Haberl EM; Spirk M; Weiss TS; Wiest R; Buechler C
Clin Exp Med; 2020 May; 20(2):289-297. PubMed ID: 32078718
[TBL] [Abstract][Full Text] [Related]
14. Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease.
Jamali R; Razavizade M; Arj A; Aarabi MH
World J Gastroenterol; 2016 Jun; 22(21):5096-103. PubMed ID: 27275102
[TBL] [Abstract][Full Text] [Related]
15. Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis.
Ferrusquía-Acosta J; Bassegoda O; Turco L; Reverter E; Pellone M; Bianchini M; Pérez-Campuzano V; Ripoll E; García-Criado Á; Graupera I; García-Pagán JC; Schepis F; Senzolo M; Hernández-Gea V
J Hepatol; 2021 Apr; 74(4):811-818. PubMed ID: 33068638
[TBL] [Abstract][Full Text] [Related]
16. Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis.
Xu G; Wang YM; Ying MM; Chen SD; Li ZR; Ma HL; Zheng MH; Wu J; Ding C
Clin Mol Hepatol; 2021 Apr; 27(2):329-345. PubMed ID: 33465844
[TBL] [Abstract][Full Text] [Related]
17. Portal vein omentin is increased in patients with liver cirrhosis but is not associated with complications of portal hypertension.
Eisinger K; Krautbauer S; Wiest R; Karrasch T; Hader Y; Scherer MN; Farkas S; Aslanidis C; Buechler C
Eur J Clin Invest; 2013 Sep; 43(9):926-32. PubMed ID: 23855493
[TBL] [Abstract][Full Text] [Related]
18. The predictive value of serum laminin for the risk of variceal bleeding related to portal pressure levels.
Kondo M; Miszputen SJ; Leite-mor MM; Parise ER
Hepatogastroenterology; 1995; 42(5):542-5. PubMed ID: 8751212
[TBL] [Abstract][Full Text] [Related]
19. Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD).
Fernández Rodríguez CM; Aller R; Gutiérrez García ML; Ampuero J; Gómez-Camarero J; Martín-Mateos RMª; Burgos-Santamaría D; Rosales JM; Aspichueta P; Buque X; Latorre M; Andrade RJ; Hernández-Guerra M; Romero-Gómez M
Rev Esp Enferm Dig; 2019 Apr; 111(4):264-269. PubMed ID: 30810330
[TBL] [Abstract][Full Text] [Related]
20. No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion.
Mortensen C; Karlsen S; Grønbæk H; Nielsen DT; Frevert S; Clemmesen JO; Møller S; Jensen JS; Bendtsen F
Liver Int; 2013 Oct; 33(9):1309-15. PubMed ID: 23763259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
